Nashville, TNNCT06178614Now EnrollingIRB Ready

Neoplasms Clinical Trial in Nashville, TN

Access cutting-edge neoplasms treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.

Sponsored by Janssen Research & Development, LLC

Quick Self-Assessment

See if you qualify for this Nashville location

Preparing your pre-screening questions…

Expert Care in Nashville

Access neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms treatment provided free

Apply for This Nashville Location

Check if you qualify for this neoplasms clinical trial in Nashville, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Nashville

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Nashville site if eligible
  4. 4Begin participation

About This Neoplasms Study in Nashville

The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

Sponsor: Janssen Research & Development, LLC

Who Can Participate

Inclusion Criteria

Have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) Renal cell cancer (RCC)-clear cell or papillary carcinoma; b) Endometrioid ovarian cancer c) Endometrioid uterine carcinoma; d) Colorectal adenocarcinoma (CRC); e) Lung adenocarcinoma
Have measurable or evaluable disease: Part 1- Either measurable or evaluable disease; Part 2- At least 1 measurable lesion per RECIST v1.1. Participants with ovarian cancer without a measurable lesion must have disease evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or have cancer antigen (CA) 125 greater than (\>) 2\*upper limit of normal (ULN) during screening
All participants in Part 1 and Part 2 must consent to provide an archived tumor tissue sample at screening
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening
Be willing and able to adhere to the lifestyle restrictions specified in this protocol.

Exclusion Criteria

Active Central Nervous System (CNS) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \[\<=\]10 milligrams \[mg\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment
Toxicity from prior anticancer therapy that has not resolved to Grade \<=1 (except alopecia, vitiligo, Grade \<=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement)
History of Grade greater than or equal to (\>=) 2 immune-related AE(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of Grade 2 and Grade 3 immune-related AEs that responded to treatment and that did not recur following rechallenge. Endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed.
History of solid organ or hematologic stem cell transplantation
Any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Nashville?

Yes, this clinical trial (NCT06178614) has an active research site in Nashville, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms Treatment Options in Nashville, TN

If you're searching for neoplasms treatment options in Nashville, TN, this clinical trial (NCT06178614) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Nashville, TN

See all myeloproliferative neoplasms clinical trials recruiting in Nashville — not just this study.

Browse Myeloproliferative Neoplasms Trials in Nashville →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Nashville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Nashville, TN